TABLE 2.
Characteristics of included studiesa
| Author(s), yr (reference no.) | Title | Treatment duration (days) | No. of subjects | Treatment | Analytical method | Drug manufacturer |
|---|---|---|---|---|---|---|
| Raaflaub and Ziegler, 1979 (22) | Single-dose pharamcokinetics of the trypanosomicide benznidazole in man | 1 | 6 | Benznidazole at 100 mg (single dose) | Differential pulse polarography | Hoffmann-La Roche |
| Bronn, 2015 (17) | A study to evaluate the food effect of a new formulation containing 100mg benznidazole. A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers | 1 | 18 | Benznidazole at 100 mg (single dose) | LC/MS-MS | Laboratorios Liconsa S.A., Spain |
| Soy et al., 2015 (25) | Population pharmacokinetics of benznidazole in adult patients with Chagas disease | 56 | 49 | Benznidazole at 2.5 mg/kg BID | HPLC | Elea Laboratory, Argentina |
| Raaflaub, 1980 (21) | Multiple-dose kinetics of the trypanosomicide benznidazole in man | 25 | 8 | Benznidazole at 3.5 mg/kg BID | Differential pulse polarography | Hoffmann-La Roche |
| Fernandez et al., 2016 (18) | Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole | 60 | 6 | Benznidazole (various doses) | HPLC | Elea Laboratory, Argentina |
| Peregrina Lucano, 2004 (20) | Farmacocinetica poblacionalde benznidazole en pacientes Mexicanos con enfermedad de Chagas | 1 | 11 | Benznidazole at 100 mg (single dose) + 2.5 mg/kg BID | HPLC | Hoffmann-La Roche |
| Bournissen, 2013 (19) | E1224 pharmacokinetics report | 60 | 45 | Benznidazole at 2.5 mg/kg BID | NR | NR |
| Roberts et al., 1984 (24) | A phase I study of the combination of benznidazole and CCNU in man | Various | 11 | Benznidazole at 25 mg/kg | HPLC | Hoffmann-La Roche |